Early hypoglycaemia after accidental intramuscular injection of insulin glargine

Diabetic Medicine

Volumn 22, Issue 10, 2005, Pages 1444-1445

  Karges, B ^a   Boehm, B O ^b   Karges, Wolfram ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Hypoglycaemia; Insulin glargine; Pharmacokinetics

Indexed keywords

INSULIN GLARGINE; ISOPHANE INSULIN;

ADULT; ARTICLE; CASE REPORT; DIET RESTRICTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; EXPERIENCE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; SIDE EFFECT;

ADULT; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAMUSCULAR; INSULIN;

EID: 25844511202     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01654.x     Document Type: Article

References (9)

1. Bolli GB, Owens DR. Insulin glargine. Lancet 2000; 356: 443-445.
2. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.
3. Scholtz HE, Pretorius SG, Wessels DH, Venter C, Potgieter MA, Becker RH. Equipotency of insulin glargine and regular human insulin on glucose disposal in healthy subjects following intravenous infusion. Acta Diabetol 2003; 40: 156-162.
4. Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000; 23: 813-819.
5. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23: 644-649.
6. Polak M, Beregszaszi M, Belarbi N, Benali K, Hassan M, Czernichow P et al. Subcutaneous or intramuscular injections of insulin in children. Are we injecting where we think we are? Diabetes Care 1996; 19: 1434-1436.
7. Vaag A, Pedersen KD, Lauritzen M, Hildebrandt P, Beck-Nielsen H. Intramuscular versus subcutaneous injection of unmodified insulin: consequences for blood glucose control in patients with type 1 diabetes mellitus. Diabet Med 1990; 7: 335-342.
8. Vaag A, Handberg A, Lauritzen M, Henriksen JE, Pedersen KD, Beck-Nielsen H. Variation in absorption of NPH insulin due to intramuscular injection. Diabetes Care 1990; 13: 74-76.
9. Tubiana-Rufi N, Belarbi N, Du-Pasquier-Fediaevsky L, Polak M, Kakou B, Leridon L et al. Short needles (8 mm) reduce the risk of intramuscular injections in children with type 1 diabetes. Diabetes Care 1999; 22: 1621-1625.